Keros to receive $20M milestone from Takeda; will distribute 25% to stockholders

Keros Therapeutics, Inc.

$20M milestone triggered by first patient dosed in Phase 3 ELRiSE MDS trial of elritercept vs epoetin alfa for anemia in low-risk MDS.
Keros to distribute 25% of net cash proceeds from milestone to stockholders after receipt.
Under existing Takeda license (Jan 2025), Keros already received $200M upfront; total milestones could exceed $1.1B plus tiered royalties.
Phase 3 ELRiSE MDS trial is open-label, randomized, multicenter; follows positive Phase 2 signals in MDS with/without ring sideroblasts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.